A Phase II, Randomised, Open Label Study of Neoadjuvant Dabrafenib, Trametinib and / or Pembrolizumab in BRAF V600 Mutant Resectable Stage IIIB/C Melanoma
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2017
At a glance
- Drugs Dabrafenib (Primary) ; Pembrolizumab (Primary) ; Trametinib (Primary)
- Indications Malignant melanoma
- Focus Therapeutic Use
- Acronyms NeoTrio
- 08 Nov 2017 Planned End Date changed from 1 Jun 2019 to 1 Nov 2019.
- 08 Nov 2017 Planned primary completion date changed from 1 Jun 2018 to 1 Nov 2018.
- 08 Nov 2017 Status changed from not yet recruiting to recruiting.